Live news related to GENFIT stock (FR0004163111): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on GENFIT mainly cover earnings publications, analyst notes et share price moves. The stock trades at €9,54 on Euronext Paris, down 9,49% at the last update. This page lists the articles published on GENFIT stock to track the share price, company announcements and any item likely to influence market perception.
The Lille-based biotech specialising in liver and metabolic diseases is retreating at midday, in a very poorly oriented Paris session. The move comes …
The Lille-based biotech specialising in liver and metabolic diseases recovers mid-session in a Paris market trending higher. After a decline the previ…
The Lille-based biotech specialising in liver and metabolic diseases recovers at the close, in a Paris market trending lower. It ranks among the index…
The Lille-based biotech specializing in liver and metabolic diseases is losing ground in mid-morning trading, in a Paris market that is clearly trendi…
The Lille-based biotech specializing in liver and metabolic diseases extends its rebound mid-session, in a well-oriented Paris market. The move follow…
The Lille-based biotech specializing in liver and metabolic diseases edges lower late in the afternoon, while the Paris market posts a clear gain. The…
The Lille-based biotech specializing in liver and metabolic diseases is recovering mid-session in a well-oriented Parisian market. The move follows a …
On November 8, 2026, in Denver at the AASLD The Liver Meeting congress, Genfit presented a detailed review of Nangibotide, its lead drug candidate in …
The Lille-based biotech specialising in liver and metabolic diseases collapses mid-session, following a publication whose figures lend themselves to t…
Genfit published its third-quarter financial results on November 5, 2026, which show two movements in opposite directions.Over the first nine months, …